The Medicines Company (MDCO) announced that a Phase 3 clinical trial, TANGO 1, evaluating its investigational antibiotic, Fast Track-tagged CARBAVANCE (meropenem-vaborbactam), for the treatment of complicated urinary tract infections (cUTI) met both FDA and EMA pre-specified endpoints, showing an overall success rate of 98.4%, statistically significantly better than piperacillin-tazobactam. TANGO 1 randomized 550 adults 1:1 to receive either CARBAVANCE via a three-hour infusion every eight hours or piperacillin-tazobactam via 30-minute infusion every eight hours, each for up to 10 days. After a minimum of five days of IV therapy, patients who met protocol-defined criteria of improvement were transitioned to oral levofloxacin.